Translate Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber/Boston Children’s assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a medical interpreter for a discussion about your care.
Displaying 31-40 of 74 results matching:
U.S. News & World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center the top pediatric cancer program in New England and #2 in the nation in its 2020-21 Best Children's Hospitals report.
A collaboration between the Finnish Cancer Registry and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center explored the utility of population-based registry data to screen childhood cancer patients for history of familial cancer. The study opened a new method for identifying high risk families that may reveal possible novel cancer predisposition genes.
The Harrington Discovery Institute and The American Society for Clinical Investigation honor Dr. Orkin for his contributions to red blood cell biology.
The report’s authors include investigators from Dana-Farber, Brigham and Women’s, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, the Broad Institute of MIT and Harvard, and Pitié-Salpêtrière hospitals in Paris, France, among others.
Daniel Bauer, MD, PhD, is a physician-scientist whose research focuses on functional genomics to dissect determinants of blood cell development and disease and develop innovative therapies.
Strategies to bar the coronavirus (COVID-19) from entering cells — thereby preventing infection and averting transmission of the virus — are among the most promising treatment approaches to COVID-19.
Dana-Farber/Boston Children’s physicians have implemented crucial testing protocols during this unusual time, with a focus that children with cancer need life-saving treatments even in the setting of a viral pandemic.
Past recipients with ties to Dana-Farber/Boston Children’s include Joanne Wolfe, MD, MPH (2016); Scott A. Armstrong, MD, PhD (2014); David Williams, MD (2006); and Stuart Orkin, MD (2003).
The patient-partnered initiative will enable anyone in the USA and Canada affected by osteosarcoma to participate.
The clinical trial will investigate the effectiveness of a combination of two oral drugs targeting the DNA damage response pathway.